0000070318-26-000012
SEC filingRevenue grew 3.1% to $21.31B, but operating margin compressed as prior-year gains from facility sales normalized.
Tenet Healthcare Corporation describes itself as a diversified healthcare services company with a nationwide care delivery network. Headquartered in Dallas, Texas, it operates through direct and indirect subsidiaries, partnerships, and joint ventures. The company also maintains a Global Business Center in the Philippines supporting enterprise-wide administrative functions.
The business is organized into two reporting segments: Hospital Operations and Services (Hospital Operations) and Ambulatory Care. Hospital Operations includes 50 acute care and specialty hospitals across eight states, a network of employed physicians, and 132 outpatient facilities such as urgent care centers, imaging centers, and off-campus emergency departments. This segment also includes Conifer Health Solutions, which provides revenue cycle management and value-based care services to approximately 600 clients, with Tenet and CommonSpirit Health representing about 44% of those clients. The Ambulatory Care segment consists of USPI, which held ownership interests in 533 ambulatory surgery centers and 26 surgical hospitals across 37 states as of December 31, 2025. USPI facilities offer procedures in orthopedics, gastroenterology, pain management, ophthalmology, and other specialties.
Key platforms include Conifer Health Solutions for revenue cycle management and value-based care, and USPI for ambulatory surgery. The company also operates joint ventures such as urgent care centers managed by NextCare in Arizona. Additionally, the Baptist School of Health Professions in San Antonio is noted for training.
Tenet’s facilities compete for patients through managed care contracts with HMOs, PPOs, and other payers. The company negotiates contracts to include all its facilities in a geographic area. Conifer sells its services to hospitals, health systems, physician practices, employers, and other entities. No single customer concentration is disclosed beyond the approximate 44% represented by Tenet and CommonSpirit facilities among Conifer’s clients.
The company faces competition from other hospitals, outpatient facilities, physician-owned centers, and larger health systems. Competitors may have advantages such as tax-exempt status, access to tax-exempt financing, or charitable endowments. Competition is based on quality, location, scope of services, reputation, and managed care relationships. The filing notes that some competitors may negotiate exclusivity with payers or form narrow networks. The market for revenue cycle management services is also competitive, requiring rapid response to changing standards.
Strategic pillars include expanding the ambulatory care business through acquisitions and organic growth, investing in the physician enterprise and specialist networks, enhancing patient and physician satisfaction, and growing higher-demand clinical service lines. The company also focuses on maintaining favorable managed care contracts, including all facilities in negotiations, and improving clinical quality through technology, equipment, and evidence-based medicine. Quality improvements are expected to reduce costs, increase payments, and improve volumes.
At December 31, 2025, Tenet employed nearly 100,000 people (99,000 total; 75,000 in Hospital Operations, 24,000 in Ambulatory Care). Approximately 23% are part-time or on-call, and 31% are nurses. About 5,600 employees work at the GBC in the Philippines. In the Hospital Operations segment, roughly 20% of employees are unionized, primarily at 27 hospitals in California, Florida, and Michigan. The company emphasizes recruiting and retaining physicians and nurses, offering competitive compensation, training programs, and an employee assistance program. Challenges include shortages of qualified personnel and wage pressures in certain markets.
For the year ended December 31, 2025, Tenet Healthcare reported consolidated net operating revenues of $21.310 billion, an increase of $635 million or 3.1% compared to 2024. The growth was primarily driven by the Ambulatory Care segment, which posted a 14.1% revenue surge to $5.172 billion, while Hospital Operations revenue remained essentially flat at $16.138 billion due to the impact of divestitures. Operating income fell sharply to $3.508 billion from $5.956 billion in the prior year, largely because 2024 included $2.916 billion in net gains on facility sales. On an adjusted basis, operating income adjusted for these gains and other items would have shown improvement from underlying operations. Operating margin decreased to 16.5% from 28.8%, reflecting the non-recurrence of those gains.
Hospital Operations same-hospital net operating revenues increased 6.5% to $15.936 billion, driven by a more favorable payer mix, higher patient admissions and acuity, growth in Medicaid supplemental revenue, and negotiated commercial rate increases. However, total segment revenue declined by $3 million due to the sale of multiple hospitals in 2024. Operating income for the segment was $1.730 billion with a 10.7% margin, down from $4.223 billion in 2024 when gains on divestitures were included. The Ambulatory Care segment continued its strong momentum, with revenue up 14.1% to $5.172 billion, largely from acquisitions and de novo developments, partly offset by facility closures. Same-facility systemwide net revenue increased 7.5%, with case volume up 0.3% and net revenue per case up 7.1%. Segment operating income reached $1.778 billion, representing a 34.4% margin, compared to 38.2% in 2024 due to higher expenses from investments and acquisitions.
Management's forward-looking commentary highlights several strategic priorities: expanding the Ambulatory Care segment through acquisitions and organic growth, driving same-hospital performance, and improving profitability through cost management and higher patient volumes. The company provided capital expenditure guidance for fiscal 2026 of approximately $700 million to $800 million, down from $1.010 billion in 2025. Additionally, annual interest payments are expected to be between $750 million and $760 million. The company also noted the recent enactment of the One Big Beautiful Bill Act (OBBBA), which introduces significant healthcare policy changes beginning in 2027, but the impact cannot be estimated at this time. The company continues to focus on managing its capital structure, having executed $2.25 billion in debt issuances and redemptions in November 2025, and repurchased $1.386 billion of common stock during the year. Management believes existing cash and borrowing capacity under the new credit facility are adequate to meet near-term needs.
Cash and equivalents decreased to $2,883M from $3,019M. Marketable securities were $59M. Total debt remained virtually unchanged at $13,171M, reflecting $2,250M of new issuances (5.500% senior secured first lien notes due 2032 and 6.000% senior unsecured notes due 2033) offset by redemptions of $2,250M (6.250% senior secured second lien notes due 2027 and $750M of 6.125% senior notes due 2028). The new revolving credit facility provides $1.9B availability. Shareholders' equity stood at $4,220M.
No material purchase commitments are disclosed. Operating lease obligations total $1,527M ($271M due in 2026). Finance lease obligations are $798M ($53M in 2026). The company has physician income guarantees with a maximum potential payment of $168M and a recorded liability of $138M.
Tenet repurchased 8.771M shares for $1,386M during 2025. As of December 31, 2025, $1,490M remained authorized under the 2024 share repurchase program, which was increased by $1.5B in July 2025. No dividends were declared. Capital expenditures totaled $1,010M (4.7% of revenue), primarily for property and equipment. Debt refinancing resulted in a net decrease of $2M.
Segment revenue is disclosed in Note 15: Hospital Operations and Services generated $16,138M (flat versus 2024), Ambulatory Care generated $5,172M (+14.1%). Hospital Operations payer mix includes Medicare ($2,119M), Medicaid ($1,524M), managed care ($9,696M), and other. The Hospital Operations segment also includes revenue cycle management services. Segment operating income is not reported in the Notes.
Tenet faces significant risks from evolving healthcare laws, particularly the expiration of Affordable Care Act provisions and the implementation of the OBBBA, which could reduce insurance coverage and shift payer mix toward government programs with lower reimbursement. Medicare and Medicaid fee-for-service revenues (26% of Hospital Operations) are vulnerable to state budget cuts and federal payment reductions. The company is also exposed to changes in managed care regulations, including the No Surprises Act, which may limit out-of-network rates.
Labor shortages remain a critical risk: 20% of employees are unionized, and competition for nurses and physicians drives wage inflation. The company relies on temporary staff and has experienced strikes. Physician recruitment is challenged by regulatory constraints and competition from health systems and private equity. Additionally, pandemic-related disruptions and supply chain issues for medical supplies could impact patient volumes and costs.
Competition from tax-supported and not-for-profit hospitals, as well as freestanding surgery centers and physician-owned facilities, pressures pricing and managed care contract terms. The No Surprises Act and price transparency initiatives further intensify competition. In the revenue cycle management market, Conifer faces competition from internal departments and other vendors.
High indebtedness ($13.2B) and interest expense ($821M) consume 23% of operating income. Restrictive covenants in debt agreements limit the ability to incur additional debt, make investments, or sell assets. The company may be forced to reduce capital expenditures or divest assets if cash flows are insufficient. Impairment charges ($61M in 2025) and restructuring costs ($44M) reflect adverse financial trends.
Tenet experienced a cybersecurity incident in April 2022, and the risk of future attacks (ransomware, data breaches) remains elevated. The company has invested in security improvements, but insurance costs have risen. The adoption of AI introduces new risks related to data privacy, output quality, and regulatory compliance. If AI systems fail, patient care or financial results could be harmed.
Tenet's cash flow from operations (CFO) of $3,540M in 2025 significantly exceeded net income of $2,367M, yielding a CFO/net income ratio of 1.5x, indicating strong cash conversion quality. Key non-cash adjustments include depreciation and amortization of $863M, stock-based compensation of $104M, and impairment charges of $130M. Working capital provided a net inflow of approximately $131M, driven by an increase in accounts payable and accrued expenses ($209M) partially offset by higher inventories and other current assets. Capital expenditures rose to $1,010M, representing a capex intensity of 28.5% of CFO. Free cash flow (CFO minus capex) was approximately $2,530M, though not explicitly stated. The company deployed capital aggressively: $1,386M in share repurchases (up 106% YoY) and $809M in distributions to noncontrolling interests. Net debt repayments totaled $96M (proceeds vs repayments). Anomalies include the swing in investing cash flow from +$3,429M in 2024 (driven by $4,981M in facility sales) to -$1,275M in 2025, as sales proceeds normalized. Tax payments decreased to $450M from $1,271M in 2024, aiding CFO. Overall, cash generation remains robust, supporting both organic investment and shareholder returns.